Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus

Dan Liu,1 Jing-Jie Bai,2 Jun-Jie Yao,1 Yong-Bo Wang,1 Tong Chen,1 Qian Xing,1 Ran Bai1 1Department of Endocrinology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Department of Endocrinology, Dalian Children’s Hospital, Dal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu D, Bai JJ, Yao JJ, Wang YB, Chen T, Xing Q, Bai R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	type 2 diabetes mellitus insulin glargine osteoporosis bone mineral density Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/7b7924b7e01445ee8fbe887c3c0c385f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b7924b7e01445ee8fbe887c3c0c385f
record_format	dspace
spelling	oai:doaj.org-article:7b7924b7e01445ee8fbe887c3c0c385f2021-12-02T14:51:56ZAssociation of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus1178-7007https://doaj.org/article/7b7924b7e01445ee8fbe887c3c0c385f2021-04-01T00:00:00Zhttps://www.dovepress.com/association-of-insulin-glargine-treatment-with-bone-mineral-density-in-peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Dan Liu,1 Jing-Jie Bai,2 Jun-Jie Yao,1 Yong-Bo Wang,1 Tong Chen,1 Qian Xing,1 Ran Bai1 1Department of Endocrinology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Department of Endocrinology, Dalian Children’s Hospital, Dalian, Liaoning, People’s Republic of ChinaCorrespondence: Dan Liu; Ran BaiDepartment of Endocrinology, First Affiliated Hospital of Dalian Medical University, Zhongshan Str.222, Dalian, 116011, People’s Republic of ChinaEmail liudandan303114@163.com; bairan5556@163.comPurpose: To assess the association of type 2 diabetes mellitus (T2DM) and insulin glargine treatment with bone mineral density (BMD) in Chinese people.Methods: This retrospective study included 50 subjects with T2DM: 25 received oral glucose-lowering medication (ORL group), and 25 received oral glucose-lowering medication in combination with insulin glargine injection (CGI group). Thirty non-diabetic control subjects were also included. BMD was measured at lumbar vertebrae 1– 4 (L1–L4), spine bone mineral density (sBMD) results summary (L2–L4), femoral neck and trochanter by dual-energy x-ray absorptiometry.Results: Compared with non-diabetic controls, people with T2DM had significantly lower mean BMD at L2 (1.073± 0.120 vs 0.984± 0.158), L3 (1.094± 0.129 vs 0.991± 0.163) and L4 (1.089± 0.130 vs 0.982± 0.165) (all P< 0.05), significantly lower levels of serum calcium (2.02± 0.22 vs 2.27± 0.17 mmol/L, P< 0.05), PTH (24.19± 9.71 vs 31.52± 8.96 pg/mL, P< 0.05), and higher serum phosphate levels (1.43± 0.37 vs 1.20± 0.15 mmol/L, P< 0.05). The CGI group had higher L2, L3 and L4 BMD and sBMD (L2–L4) (P< 0.05), higher serum calcium levels (2.19± 0.11 vs 1.98± 0.20 mmol/L, P< 0.05) and lower serum phosphate levels (1.28± 0.20 vs 1.58± 0.43 mmol/L, P< 0.05) versus the ORL group. BMD and serum calcium levels were associated with the application of insulin glargine.Conclusion: These results suggest that insulin glargine may affect bone metabolism in patients diagnosed with T2DM. The study has implications for the selection of hypoglycemic agents for diabetic patients at risk of osteoporosis.Keywords: type 2 diabetes mellitus, insulin glargine, osteoporosis, bone mineral densityLiu DBai JJYao JJWang YBChen TXing QBai RDove Medical Pressarticletype 2 diabetes mellitusinsulin glargineosteoporosisbone mineral densitySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 1909-1917 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes mellitus insulin glargine osteoporosis bone mineral density Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes mellitus insulin glargine osteoporosis bone mineral density Specialties of internal medicine RC581-951 Liu D Bai JJ Yao JJ Wang YB Chen T Xing Q Bai R Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
description	Dan Liu,1 Jing-Jie Bai,2 Jun-Jie Yao,1 Yong-Bo Wang,1 Tong Chen,1 Qian Xing,1 Ran Bai1 1Department of Endocrinology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Department of Endocrinology, Dalian Children’s Hospital, Dalian, Liaoning, People’s Republic of ChinaCorrespondence: Dan Liu; Ran BaiDepartment of Endocrinology, First Affiliated Hospital of Dalian Medical University, Zhongshan Str.222, Dalian, 116011, People’s Republic of ChinaEmail liudandan303114@163.com; bairan5556@163.comPurpose: To assess the association of type 2 diabetes mellitus (T2DM) and insulin glargine treatment with bone mineral density (BMD) in Chinese people.Methods: This retrospective study included 50 subjects with T2DM: 25 received oral glucose-lowering medication (ORL group), and 25 received oral glucose-lowering medication in combination with insulin glargine injection (CGI group). Thirty non-diabetic control subjects were also included. BMD was measured at lumbar vertebrae 1– 4 (L1–L4), spine bone mineral density (sBMD) results summary (L2–L4), femoral neck and trochanter by dual-energy x-ray absorptiometry.Results: Compared with non-diabetic controls, people with T2DM had significantly lower mean BMD at L2 (1.073± 0.120 vs 0.984± 0.158), L3 (1.094± 0.129 vs 0.991± 0.163) and L4 (1.089± 0.130 vs 0.982± 0.165) (all P< 0.05), significantly lower levels of serum calcium (2.02± 0.22 vs 2.27± 0.17 mmol/L, P< 0.05), PTH (24.19± 9.71 vs 31.52± 8.96 pg/mL, P< 0.05), and higher serum phosphate levels (1.43± 0.37 vs 1.20± 0.15 mmol/L, P< 0.05). The CGI group had higher L2, L3 and L4 BMD and sBMD (L2–L4) (P< 0.05), higher serum calcium levels (2.19± 0.11 vs 1.98± 0.20 mmol/L, P< 0.05) and lower serum phosphate levels (1.28± 0.20 vs 1.58± 0.43 mmol/L, P< 0.05) versus the ORL group. BMD and serum calcium levels were associated with the application of insulin glargine.Conclusion: These results suggest that insulin glargine may affect bone metabolism in patients diagnosed with T2DM. The study has implications for the selection of hypoglycemic agents for diabetic patients at risk of osteoporosis.Keywords: type 2 diabetes mellitus, insulin glargine, osteoporosis, bone mineral density
format	article
author	Liu D Bai JJ Yao JJ Wang YB Chen T Xing Q Bai R
author_facet	Liu D Bai JJ Yao JJ Wang YB Chen T Xing Q Bai R
author_sort	Liu D
title	Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
title_short	Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
title_full	Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
title_fullStr	Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
title_full_unstemmed	Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
title_sort	association of insulin glargine treatment with bone mineral density in patients with type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/7b7924b7e01445ee8fbe887c3c0c385f
work_keys_str_mv	AT liud associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus AT baijj associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus AT yaojj associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus AT wangyb associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus AT chent associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus AT xingq associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus AT bair associationofinsulinglarginetreatmentwithbonemineraldensityinpatientswithtype2diabetesmellitus
_version_	1718389455266512896

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus

Ejemplares similares